Larimar Therapeutics (LRMR)
(Delayed Data from NSDQ)
$4.25 USD
-0.11 (-2.52%)
Updated Oct 13, 2025 04:00 PM ET
After-Market: $4.24 -0.01 (-0.24%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LRMR 4.25 -0.11(-2.52%)
Will LRMR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for LRMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LRMR
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
LRMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Other News for LRMR
Is LRMR signaling selling opportunity? Fell Below 20 Day Moving Average shows up after slipping 4.18%
LRMR forms NR7 on October 9
Calm After Storm appears for LRMR after 2.12% move
Calm After Storm appears for LRMR after 1.87% move
Truist Financial Sticks to Its Buy Rating for Larimar Therapeutics (LRMR)